An extensive genomic study of the childhood cancer neuroblastoma reinforces the challenges in treating the most aggressive forms of this disease. Contrary to expectations, the scientists found relatively few recurrent gene mutations—mutations that would suggest new targets for neuroblastoma treatment. Instead, say the researchers, they have now refocused on how neuroblastoma tumors evolve in response to medicine and other factors.
"This research underscores the fact that tumor cells often change rapidly over time, so more effective treatments for this aggressive cancer will need to account for the dynamic nature of neuroblastoma," said study leader John M. Maris, M.D., director of the Center for Childhood Cancer Research at The Children's Hospital of Philadelphia (CHOP).
Striking the peripheral nervous system, neuroblastoma usually appears as a solid tumor in a young child's chest or abdomen. It comprises 7 percent of all childhood cancers, but causes 10 to 15 percent of all childhood cancer-related deaths. Neuroblastoma is notoriously complex, with a broad number of gene changes that can give rise to the disease.
Maris headed the multicenter research collaborative, the TARGET (Therapeutically Applicable Research to Generate Effective Treatments) initiative, which released its findings today in Nature Genetics. This largest-ever study genomic study of a childhood cancer analyzed DNA from 240 children with high-risk neuroblastomas. Using a combination of whole-exome, whole-genome and transcriptome sequencing, the study compared DNA from tumors with DNA in normal cells from the same patients.
Researchers at CHOP and other centers previously discovered neuroblastoma-causing mutations, such as those in the ALK gene. In the subset of patients carrying this mutation, oncologists can provide effective treatments tailored to their genetic profile.
"A few years ago, we thought we would be able to sequence the genomes of individual patients with neuroblastoma, detect their specific cancer-causing mutations, and then select from a menu of treatments," said Maris. The oncology researchers designed the TARGET study to perform genomic analyses of a large cohort of high-risk neuroblastoma patients, with the goal of mapping out a limited number of treatment strategies. This approach would represent a significant step forward in personalizing neuroblastoma therapy.
However, while the researchers confirmed that roughly 10 percent of the study's neuroblastoma patients had ALK mutations, and found that a handful of other gene mutations each accounted for percentages in the single digits, there were relatively few recurrent mutations in somatic (non-germline) cells. "The relative paucity of recurrent mutations challenges the concept that druggable targets can be defined in each patient by DNA sequencing alone," wrote the authors.
In the absence of frequently altered oncogenes that drive high-risk neuroblastomas, the authors concluded that most such cases may result from other changes: rare germline mutations, copy number variations and epigenetic modifications during tumor evolution.
"Personalized medicine is more complex than we had hoped," said Maris. "While there are successes such as those in treating patients whose tumors harbor ALK mutations, this study implies that we must think very differently about how we'll use genomics to define treatment." Maris added that neuroblastoma researchers may need to turn to functional genomics, learning which tumors will or won't respond to treatments, as well as going beyond a static picture of a cancer cell with fixed genetic contents, to devising interventions to deal with dynamic tumor cells that evolve during nervous system development.
"The genetic landscape of high-risk neuroblastoma," Nature Genetics Advance online publication, Jan. 20, 2013.
Children's Hospital of Philadelphia: http://www.chop.edu
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
Like any trench war, the fight to protect America's kids against disease is proceeding only inch by inch. A new report shows why there's reason for hope—and reason for worry
Decontaminating biohazard sites can be a tough job, but the hardest microbe to wash away may not be what you think
The discovery of a possible trigger for the onset of Parkinson's disease could lead to new treatments for patients who still depend on a 50-year-old drug
Many people experience severe anxiety in mundane social situations, such as group introductions or paying bills. Why does this happen? And is there any useful purpose to it?
Along with the usual suspects, cigarettes and booze, the European code for avoiding cancer has been updated to include having the HPV vaccine and breastfeeding
Lose the pounds too fast, gain them all back? It seems not. Crash dieters regain the same amount of lost weight as those taking a longer-term approach
A new study suggests a little spending now can buy you a lot of time later
Researchers have identified a chemical that melanoma cells follow when they spread around the body raising the prospect of eventually switching it off
Some of the planet’s scariest, most lethal viruses find a natural refuge inside bats, including Ebola, rabies, Marburg and the SARS coronavirus. Many high-profile epidemics have been traced back to bats, and scientists are discovering new bat-borne viruses all the time.
Women's voices are often criticized, especially at work. We're called "shrill," told we "lack authority." Here's the story of two women who changed their voices in a quest to be heard.